FIGURE 3 from Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers
Year: 2024
Type: other
Abstract: Signaling, cell cycle, and clonogenic analysis of combined erlotinib and alisertib in KRASmut NSCLC cells. A, Quantification of Western analysis of drug-treated cells using indicated antibodies, based on five to eight replicates. Cells were treated for 24 hours with concentrations reflecting the IC80 value of erlotinib and/or alisertib (9 µmol/L erlotinib: 13 µmol/L alisertib, in A549 cells, or 2.8 µmol/L erlotinib: 4.2 µmol/L alisertib in H358 cells). Primary Western blot data are shown in Supplementary Fig. S1. B, FACS analysis of cell cycle in H358 and A549 cells treated for 24 or 72 hours with drug concentrations 0.2 µmol/L erlotinib: 300 nmol/L alisertib, in A549 cells, or 1.2 µmol/L erlotinib: 1.8 µmol/L alisertib in H358 cells; three to four biological replicates, data shown represent averaged values. Representative data from clonogenic assays (C) and quantitation of images from three biological replicates (D), for the indicated cell lines treated with negative control, 75 nmol/L erlotinib, 25 nmol/L alisertib, or the combination for 10 days. Statistical comparisons are to control (red), combination to erlotinib (orange) or alisertib (green), alisertib to erlotinib (purple). *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4396733973